Results 21 to 30 of about 32,890 (266)

Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn’s Diseasesummary

Cellular and Molecular Gastroenterology and Hepatology, 2021
Background & aims: The pathogenesis of chronic inflammatory bowel diseases (Crohn’s disease [CD] and ulcerative colitis) involves dysregulated TH1 and TH17 cell responses, which can be targeted therapeutically by the monoclonal antibody Ustekinumab ...
Anna-Maria Globig, Nikola Patricia Sommer, Katharina Wild, Josefine Schardey, Katharina Zoldan, Anne Kerstin Thomann, Lucas-Alexander Schulte, Rupert Schreiner, Wolfgang Reindl, Jochen Klaus, Christoph Mathis Schempp, Maike Hofmann, Robert Thimme, Tobias Boettler, Peter Hasselblatt   +14 more
doaj   +1 more source

Clinical consequences of antibody formation, serum concentrations, and HLA-Cw6 status in psoriasis patients on Ustekinumab [PDF]

, 2019
Background: Ustekinumab for the treatment of psoriasis is currently administered in a standard dosing regimen. However, some patients tend to benefit from alternative dosing regimens, a step toward personalized medicine.
Busard, Celine, I, Costanzo, Antonio, De Keyser, Eline, Hutten, Barbara A., Lambert, Jo, Lanssens, Sven, Meuleman, Lieve, Spuls, Phyllis, I, van den Reek, Juul M., Zweegers, Jeffrey   +9 more
core   +1 more source

Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: the IM-UNITI trial.

Clinical Gastroenterology and Hepatology, 2021
BACKGROUND AND AIMS The IM-UNITI study and long-term extension (LTE) evaluated the long-term efficacy, safety, and immunogenicity of subcutaneous ustekinumab maintenance therapy in patients with Crohn's disease (CD).
W. Sandborn, R. Rebuck, Yuhua Wang, B. Zou, O. Adedokun, C. Gasink, B. Sands, S. Hanauer, S. Targan, Subrata Ghosh, W. D. de Villiers, J. Colombel, B. Feagan, J. Lynch   +13 more
semanticscholar   +1 more source

Viewpoint on handling anti-TNF failure in psoriasis [PDF]

, 2013
An association among the occurrence of antidrug antibodies (ADAs), diminished trough serum drug levels (TSDLs) and non-response or loss of response has been described for several tumor necrosis factor alpha (TNF) blocking agents in a variety of diseases,
BRACKE, STEFANIE, Lambert, Jo
core   +1 more source

Ustekinumab Dosing Individualization in Crohn’s Disease Guided by a Population Pharmacokinetic–Pharmacodynamic Model

Pharmaceutics, 2021
Ustekinumab is a monoclonal antibody used in Crohn’s disease (CD). Dose optimization in case of non-response and the role of pharmacokinetic–pharmacodynamic (PK-PD) monitoring remain unresolved dilemmas in clinical practice.
Jurij Aguiar Zdovc, Jurij Hanžel, Tina Kurent, Nejc Sever, Matic Koželj, Nataša Smrekar, Gregor Novak, Borut Štabuc, Erwin Dreesen, Debby Thomas, Tomaž Vovk, Barbara Ostanek, David Drobne, Iztok Grabnar   +13 more
doaj   +1 more source

Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study [PDF]

, 2018
Background: Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque psoriasis patients. Objective: To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics.
Armesto, Burmester, Carrera, Davison, Edson-Heredia, Elm, Gisondi, Gisondi, Gisondi, Gordon, Gossec, Gossec, Gottlieb, Griffiths, Gupta, Honda, Kurd, Lernia, Lernia, López-Ferrer, Lümig, Menter, Menter, Menter, Mrowietz, Nestle, Ortonne, Papoutsaki, Papp, Papp, Papp, Papp, Salvarani, Sbidian, Simone, Strober, Talamonti, Talamonti, Talamonti, Vandenbroucke, Vollenhoven   +40 more
core   +1 more source

Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]

, 2017
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K., Mantravadi, Santhi, Ogdie, Alexis   +2 more
core   +2 more sources

Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy

Nature Communications, 2022
The function of interleukin-22 (IL-22) in intestinal barrier homeostasis remains controversial. Here, we map the transcriptional landscape regulated by IL-22 in human colonic epithelial organoids and evaluate the biological, functional and clinical ...
P. Pavlidis, Anastasia Tsakmaki, Eirini Pantazi, Katherine Li, D. Cozzetto, Jonathan Digby- Bell, Feifei Yang, J. Lo, E. Alberts, Ana Caroline Costa Sa, U. Niazi, Joshua R. Friedman, Anna K. Long, Yuchun Ding, Christopher D. Carey, C. Lamb, M. Saqi, M. Madgwick, L. Gul, A. Treveil, T. Korcsmáros, T. Macdonald, Graham M Lord, G. Bewick, N. Powell   +24 more
semanticscholar   +1 more source

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Journal of Crohn's & Colitis, 2022
Background and Aims The UNIFI long-term extension [LTE] study reports the efficacy and safety of subcutaneous 90 mg ustekinumab through 3 years of maintenance therapy. Methods Patients randomised to ustekinumab every 12 weeks [q12w] or every 8 weeks [q8w]
M. Abreu, D. Rowbotham, S. Danese, W. Sandborn, Y. Miao, Hongyan Zhang, I. Tikhonov, R. Panaccione, T. Hisamatsu, E. Scherl, Rupert Leong, R. Arasaradnam, W. Afif, L. Peyrin-Biroulet, B. Sands, C. Marano   +15 more
semanticscholar   +1 more source

Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease

Case Reports in Gastroenterology, 2018
Biological agents are frequently used in the management of inflammatory bowel disease, and it is important to understand the potential adverse effects of these therapies. Ustekinumab is a human monoclonal antibody that interferes with interleukin-12 and -
Avantika Mishra, Darren N. Seril
doaj   +1 more source